The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective was to assess brolucizumab's potential for long durability up to 20 weeks. All eligible participants were treated with brolucizumab regardless of their treatment in the TALON study. The study period was 56 weeks including post-treatment follow-up.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye
Timeframe: Up to Week 56
Average Change in BCVA From Baseline to Week 52 and Week 56 for the Study Eye
Timeframe: Extension study baseline, average of Week 52 and Week 56